 Cytokinetics Incorporated NASDAQ: CYTK has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 CK-274 in hypertrophic cardiomyopathy HCM. The Company plans to initiate Phase 3 trial by the end of 2021. 